DR. J. CLEEMPUT
The computed 12-month bankruptcy probability of DR. J. CLEEMPUT is 2.4% (moderate). The 2025 annual accounts show equity of €325k and a net result of €174k. Equity is growing by ~94.1% per year across the filed fiscal years. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €325k |
| Net result | €174k |
| Active | 3 yrs |
| Locations | 1 |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €229k |
| Net profit | €174k |
| Cash flow | €176k |
| Staff costs | - |
| Income taxes | €52k |
| Dividends | €860 |
| Total assets | €349k |
| Equity | €325k |
| Debt | €25k |
| of which ≤ 1y | €24k |
| of which > 1y | - |
| Working capital | €315k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 14.12 |
| Quick ratio | 14.12 |
| Working capital ratio | 90.2% |
| Solvency | 93.0% |
| Debt / equity | 0.08 |
| Long-term debt ratio | - |
| Interest coverage | 271.13 |
| Gross margin | - |
| Net margin | - |
| ROA | 49.8% |
| ROE | 53.6% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €349k |
| Fixed assets | 21/28 | €9k |
| Formation expenses | 20 | €2k |
| Tangible fixed assets | 22/27 | €3k |
| Financial fixed assets | 28 | €6k |
| Current assets | 29/58 | €339k |
| Amounts receivable within one year | 40/41 | €2k |
| Investments | 50/53 | €30k |
| Cash & bank | 54/58 | €258k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €349k |
| Equity | 10/15 | €325k |
| Contributions / capital | 10/11 | €1k |
| Reserves | 13 | €324k |
| Accumulated profits (losses) | 14 | €0 |
| Amounts payable | 17/49 | €25k |
| Amounts payable within one year | 42/48 | €24k |
| Trade debts payable within one year | 44 | €758 |
| Income statement | ||
| Gross operating margin | 9900 | €229k |
| Operating result | 9901 | €227k |
| Financial charges | 65 | €845 |
| Result before taxes | 9903 | €226k |
| Income taxes | 67/77 | €52k |
| Net result for the period | 9904 | €174k |
| Result to be appropriated | 9905 | €174k |
| NACE primary | - |
| Legal form | Private limited company(610) |
| Incorporation | 06-10-2022 |
| Status | Active |
| Postal code | 2800 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11013A0163/00C000 | Flanders | 397 m² | 1 · 177 m² | 10.2 m · 3 fl. |
| 12025D0923/00B000 | Flanders | 175 m² | 1 · 64 m² | 13.1 m · 3 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | DR. J. CLEEMPUT |